Beam Therapeutics (BEAM) said Monday it has priced an underwritten offering of 16.2 million shares at $28.48 per share, and pre-funded warrants to purchase 1.4 million shares at $28.47 per pre-funded warrant.
Gross proceeds from the offering, expected to close Tuesday, are anticipated to be about $500.0 million, the company said.
Beam said intends to use net proceeds from the offering for technology advancement, research and development, and other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.